Arthur A. Levin - Apr 3, 2024 Form 4 Insider Report for Avidity Biosciences, Inc. (RNA)

Role: Director
Signature: /s/ John W. Wallen III, Ph.D., J.D., Attorney-in-Fact
Stock symbol: RNA
Transactions as of: Apr 3, 2024
Transactions value $: -$542,214
Form type: 4
Date filed: 4/3/2024, 08:26 PM
Previous filing: Mar 21, 2024
Next filing: Apr 22, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RNA	Common Stock	Sale	-$542K	-20K	-7.3%	$27.11	254K	Apr 3, 2024	By family trust	F1
holding	RNA	Common Stock						14.8K	Apr 3, 2024	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.28. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2	Includes the following securities previously acquired by the Reporting Person: (i) 13,500 RSUs under the Issuer's 2020 Incentive Award Plan and (ii) 1,330 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan.

Content

This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.28. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Includes the following securities previously acquired by the Reporting Person: (i) 13,500 RSUs under the Issuer's 2020 Incentive Award Plan and (ii) 1,330 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan.